Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-10-30T17:47:49.148Z Has data issue: false hasContentIssue false

ABSORPTION AND DISTRIBUTION OF ULTRATRACE EXOGENOUS 14C UREA IN RATS

Published online by Cambridge University Press:  16 May 2024

Li Wang
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China School of Physics, Hubei University, Wuhan Hubei 430062, China
Hongtao Shen*
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
Junsen Tang
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
Guofeng Zhang
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
Linjie Qi
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
Dingxiong Chen
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
Kaiyong Wu
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
Xinyi Han
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
He Ouyang
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
Yun He
Affiliation:
Guangxi Key Laboratory of Nuclear Physics and Technology, Guangxi Normal University, Guilin 541004, China
Pucheng Yang
Affiliation:
Guilin Medical University, Guilin 541004, China
Xue Zhang
Affiliation:
Guilin Medical University, Guilin 541004, China
Chunbo Xia
Affiliation:
Guilin Medical University, Guilin 541004, China
*
*Corresponding author. Email: shenht@gxnu.edu.cn
Rights & Permissions [Opens in a new window]

Abstract

The absorption and distribution of radiocarbon-labeled urea at the ultratrace level were investigated with a 14C-AMS biotracer method. The radiopharmaceutical concentrations in the plasma, heart, liver, spleen, lung, kidney, stomach, brain, bladder, muscle, testis, and fat of rats after oral administration of 14C urea at ultratrace doses were determined by AMS, and the concentration-time curves in plasma and tissues and pharmacokinetic distribution data were obtained. This study provides an analytical method for the pharmacokinetic parameters and tissue distribution of exogenous urea in rats at ultratrace doses and explores the feasibility of evaluation and long-term tracking of ultratrace doses of drugs with AMS.

Type
Conference Paper
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of University of Arizona

INTRODUCTION

Accelerator mass spectrometry (AMS) is a technology with an extremely high isotope detection sensitivity. Compared with conventional detection methods, it has the advantages of a short measurement time, small sample amount, and high measurement sensitivity (Bennett et al. Reference Bennett, Beukens and Clover1997; Nelson et al. Reference Nelson, Korteling and Stott1977). As the most sensitive method for measuring 14C, the method is widely used in archaeology, environmental science, geology, oceanography, biomedicine, and other fields (Nielsen, Reference Nielsen1952; Lubritto et al. Reference Lubritto, Rogalla and Rubino2004; Marzaioli et al. Reference Marzaioli and Lubritto2005; Mary et al. Reference Mary2011; Salehpour et al. Reference Salehpour, Hakansson and Possnert2015; Cheng et al. Reference Cheng, Burr and Zhou2019). Since the U.S. Food and Drug Administration (FDA) has used the pharmacokinetic data of radioisotope-labeled drugs as an essential basis for the safety evaluation of new drugs and formulated corresponding regulations (FDA, 2010), similar regulations have also been formulated around the world for the early development and the later application of drugs. Therefore, radioactive tracer technology has been used in more than 80% of drugs to investigate absorption, distribution, metabolism, and excretion (Lappin and Garner, Reference Lappin and Garner2005).

The main detection methods used in isotope tracing technology include liquid scintillation (LSC) (L’Annunziata and Kessler, Reference L’Annunziata and Kessler1998), autoradiography (ARG) (Partridge et al. Reference Partridge, D’Souza and Lenz2008), and positron emission computerized tomography (PET) (Li et al. Reference Li and Conti2010). The miniaturization of PET and the development of QWBA technology have made the localization of radiolabeled drugs in organisms easier and more intuitive (Li et al. Reference Li, Xie and Zhang2008; Weiss et al. Reference Weiss, Wirz and Schweitzer2007; D’souza et al. Reference D’Souza, Partridge and Roberts2007). However, due to the limitation of measurement sensitivity, conventional detection techniques cannot measure ultratrace doses of drugs or track radiolabeled drugs for a long time (Lappin and Garner, Reference Lappin and Garner2003). On the other hand, the high sensitivity and extremely low detection limit of AMS technology allows the administration of subpharmacological doses of radiolabeled drugs to animals or humans at radiologically unremarkable levels to obtain preliminary information on drug absorption, distribution, metabolism, and excretion and has been increasingly valued by the pharmaceutical industry (Sandhu, Reference Sandhu2004). To date, most studies on the metabolism and treatment of exogenous organisms in AMS have focused on the combination of carcinogens with DNA and proteins (Turteltaub et al. Reference Turteltaub, Felton and Gledhill1990, Reference Turteltaub, Mauthe and Dingley1997), and there are fewer studies in the pharmaceutical field under the conditions of ultratrace dose administration and subpharmacological doses (Kaye et al. Reference Kaye, Garner and Mauthe1997; Young et al. Reference Young, Ellis and Ayrton2008).

In our study, AMS technology was used to measure the absorption and distribution of 14C urea in rats treated with ultratrace doses, verify the feasibility of AMS technology in ultratrace dose drug research and long-term drug tracking at the technical level, and assess the pharmacokinetic characteristics of the drug, which provides a reference for the use of AMS technology in the evaluation of ultratrace-dosing drug research and research on human subjects.

MATERIALS AND METHODS

Chemicals

14C urea capsules (SFDA #H20000020) were obtained from Shenzhen Zhonghe Headway Biotechnology Co., Ltd., China, CuO powder (GB/T674-2003, purity: ≥99.0%) was obtained from Sinopharm Chemical Reagent Co., Ltd., Fe powder (#209309, 325 mesh, 97%) was obtained from Sigma–Aldrich USA, and Zn powder (#324930, <150 µm, 99.995%) was obtained from Sigma–Aldrich USA.

Dosage

14C urea was dissolved in distilled water at a dose of 4.302 × 10–7 mg/mL. The oral dose administered to rats was 2.044 × 10–6 mg/kg bdw (body weight), and the radioactive dose was 2.058 × 10–3 μCi/kg bdw, six orders of magnitude lower than the conventional dose (Nomura et al. Reference Nomura and Matsumoto2006; Park et al. Reference Park, Dae and Han2012).

Animals

Twenty-four male Sprague–Dawley rats (SPF, Guilin Medical College, Guilin, China) weighing 243–370 g were used.

Animal Experiment

Rats were kept in individual metabolism cages in a room with a temperature of 21°C–25°C and humidity of 50–60% with a daily light/dark schedule of 12/12 hr, with free access to water throughout acclimatization. Food was removed for 12 rh before experiments and for an additional 12 hr after administration of 14C urea. Intragastric administration was performed at doses of 2.044 ×10–6 mg/kg bdw (2.058 ×10–3 μCi/kg bdw) with a stomach tube. The sampling time was 0.25 hr, 0.5 hr, 1 hr, 4 hr, 8 hr, 24 hr, and 72 hr, and 3 rats were dissected and sampled at each sampling time (the method of sacrifice was spinal dislocation) for collection of biological samples such as plasma, heart, liver, spleen, lung, kidney, stomach, brain, bladder, fat, muscle, and gonads. A blank control group (3 rats, no drug) was used for comparison. All experiments were conducted in accordance with the ethical guidelines of the Ministry of Health of China.

Sample Preparation for AMS Measurement

The collected biological samples were packed into 3–20 mL glass vials and placed in a vacuum lyophilizer for a 48 hr drying process at –70°C, after which the samples were ground and stored at –20°C. The carbon content of plasma and various blank tissue samples was measured by an elemental analyzer (manufacturer: Elementar, model: UNICUBE). The biological sample containing 1 mg of carbon was mixed with CuO powder (pretreatment at 900°C for 3 hr) at a ratio of 1:40 in the combustion tube in the vacuum sample preparation device for evacuation, as shown in Figure 1 (Shen et al. Reference Shen, Tang and Wang2022a, Reference Shen, Shi and Tang2022b). The combustion tube was sealed with a flame after the vacuum was lower than 5×10–4 mbar and placed in a muffle furnace at 900°C for 3 hr to fully react with the sample and generate CO2. Then, the combustion tube was crushed in a crushing device of the vacuum line. The CO2 gas first passed through the alcohol liquid nitrogen cold traps at –90°C to thoroughly remove the water vapor and then entered the liquid nitrogen cold trap at –196°C, where it was frozen. Any noncondensable gases, such as SO2, N2, and O2, were pumped away. The purified CO2 was heated, transferred to a reduction tube using a liquid nitrogen cold trap, and finally sealed with a torch. The reduction tube was preloaded with 15–25 mg Zn powder and 2.5–3.0 mg Fe powder and pretreated at 400°C for 3 hr. The reduction tube was then subjected to reduction treatment in the graphite reduction furnace at 650°C for 8 hr so that the CO2 reacted with Zn to produce graphite on the surface of Fe (Jull et al. Reference Jull, Donahue and Hatheway1986; Slota et al. Reference Slota, Jull and Linick1987), as shown in Figure S1. Finally, the graphite and Fe powder were pressed into the AMS cathodes for measurement.

Figure 1 A glass vacuum line for graphite preparation.

Measurement of Radioactivity

The GXNU-AMS instrument (Shen et al. Reference Shen, Tang and Wang2022a, Reference Shen, Shi and Tang2022b) was mainly composed of a cesium negative ion sputtering source, preacceleration line, injection magnet, main acceleration line, gas stripper, analysis magnet, electrostatic analyzer, and detector, as shown in Figure S2. The processed blank samples, experimental samples, and standard samples (OX-II, IAEA-C8, IAEA-C1) were installed in the cathode wheel of the ion source, as shown in Figure S3. The negative ion beam C was extracted from the ion source and then entered a double-focusing dipole injection magnet through a preacceleration tube for mass selection. An alternating high-frequency potential (Trek 10/10B-HS) was applied to the vacuum box in the injection magnet for the high-speed alternating injection of C isotopes 12C, 13C, and 14C, which were focused by an electric quadrupole triplet lens and then accelerated into the gas stripper through a 150-kV accelerating tube. He in the gas stripper stripped and converted the negatively charged ions into neutral or positive charge states, while the negative molecular ions (12CH2 , 13CH, etc.) were dissociated into their component atoms, which entered the analysis magnet at the high energy end for ion momentum/charge selection, then via the electrostatic analyzer for ion energy/charge selection to eliminate various scattered particles. Finally, the pure 14C+ entered the end detector for counting. In addition, 12C and 13C beam values were recorded in Faraday cups at the low and high energy sides for isotope fractionation correction and 14C/12C abundance calculation of the samples. The measured values of the biological samples were calibrated with the standard samples, and then the drug concentration was analyzed by Equation (1).

(1) $${\rm C} = {R_{{{_{}^{14}C} \over {_{}^{12}C}}}} \times P/\;B$$

where C is the 14C urea concentration in plasma and tissues, R is the abundance ratio of 14C/12C, P is the content of carbon in the plasma or tissue, and B is the content of carbon in urea.

RESULTS AND DISCUSSION

Carbon Recovery from the Biological Sample

Similar to the methods described by Walker et al. (Reference Walker and Xu2019) and Orsovszki et al. (Reference Orsovszki and Rinyu2015), a temperature gradient was applied to the graphite reduction process. The Fe and Zn catalysts were held at high reaction temperatures (∼600°C), whereas the tops of the Zn tube reactors were held at ambient temperatures (20–25°C). The gaseous Zn and ZnO generated during the reaction process were sequentially condensed on the cooler part (between 450°C and room temperature) of the reduction tube, as shown in Figure S4, to avoid condensation on the surface of Fe powder affecting the sample purity and improve the graphite synthesis efficiency. The average graphite recovery rate treated by this method was approximately 90% with a small fluctuation (Figure 2), which proves the stability and reliability of our vacuum 14C preparation device.

Figure 2 Graphite recovery of biological samples.

Carbon Content of Plasma and Tissues

The biocarbon contents of the vacuum-dried plasma and tissue samples were measured with the CHNS mode of the elemental analyzer (Elemental UNICUBE), similar to the method described by Lappin and Garner (Reference Lappin and Garner2005), which was used to calculate the drug concentration of 14C urea. The measurement results are shown in Table 1.

Table 1 Biological C, H, N, and S content in dried plasma and tissues.

14C Urea Concentrations in Plasma

The relationship between the radiopharmaceutical concentration in plasma and time following oral administration of 14C urea is shown in Figure 3. The metabolic data were pharmacokinetically processed using Phoenix Winnonlin 8.1 (Certara, USA) software (Schütz, Reference Schütz2012), as shown in Table 2. The rapid peak time of 14C urea absorption was only 0.25 hr, with a peak concentration of 1.323×10−3 ng/mL, an average retention time of 23.49 hr, a steady-state distribution volume of 3.403 mL/kg, and a clearance rate of 79.95 mL/h/kg.

Figure 3 Radiopharmaceutical concentrations in plasma of rats after oral administration of 14C urea.

Table 2 Pharmacokinetic parameters of 14C-urea determined by accelerator mass spectrometry after oral administration in fasted rats.

14C Urea Distribution in Tissues

The measurement data of the radiopharmaceutical concentration in different tissues of rats at 0.25 hr, 0.5 hr, 1 hr, 4 hr, 8 hr, 24 hr, and 72 hr after oral administration of 14C urea are shown in Table 3, Figure 4, and Figure S5. As shown in the data, the presence of 14C urea was detected in all 11 tissues and plasma, with the radiopharmaceutical concentration peaking at 0.25 hr in plasma and liver, at 0.5 hr in heart, spleen, lung, kidney, stomach, bladder, fat, and muscle, and at 4 hr in brain and testis.

Table 3 14C-urea concentrations in tissues after oral administration in fasted rats.

a The unit is only for plasma.

Figure 4 14C-urea concentrations in tissues of rats after oral administration of 14C urea.

The radiopharmaceutical concentrations in the heart, liver, spleen, lung, kidney, stomach, bladder, fat, muscle, and testis were higher than that in plasma, and the peak value of concentration in each organ concentration was 4.987×10−3 ng/g, 4.551×10−3 ng/g, 6.060×10−3 ng/g, 4.263×10−3 ng/g, 3.159×10−2 ng/g, 1.296×10−2 ng/g, 3.324×10−3 ng/g, 2.456×10−2 ng/g, 5.612×10−3 ng/g, 3.665×10−3 ng/g, and 9.418×10−3 ng/g, respectively, which is similar to the distribution of urea in rats at conventional doses (Nomura et al. Reference Nomura and Matsumoto2006; Park et al. Reference Park, Dae and Han2012). The order of the radiopharmaceutical concentration in each tissue was kidney > bladder > stomach > testis > spleen > fat > heart > liver > lung > muscle > brain.

The radiopharmaceutical concentrations in the stomach, kidney, and bladder were much higher than those in other tissues, suggesting that urinary excretion is a major excretion route for 14C urea, which is similar to the metabolic trend of urea at conventional doses (Nomura et al. Reference Nomura and Matsumoto2006; Park et al. Reference Park, Dae and Han2012; Dickerson et al. Reference Dickerson, Lee and Keshava2018; Rapoport et al. Reference Rapoport, Fitzhugh and Pettigrew1982; Juhr et al. Reference Juhr and Franke1987, Reference Juhr and Franke1990). Drug concentrations in the brain, fat, and muscle were low, indicating that 14C urea did not easily enter highly lipidic tissues. The radiopharmaceutical concentration in the plasma decreased continuously from 0.25 hr to 72 hr, the radiopharmaceutical concentrations in all tissues were at a low level 24 hr after administration, and most of the drug and metabolites had been eliminated from the body. The measured radiopharmaceutical concentrations in plasma and tissue dropped to background levels at 72 hr, and no specific tissue accumulation of urea was detected.

CONCLUSIONS

Ultratrace dose pharmacokinetic studies can provide pharmacokinetic parameters and distribution data beyond conventional doses, which play an essential role in the drug development process and help to select the most suitable drug for further clinical evaluation. In this study, we investigated the absorption and distribution of 14C urea at an oral ultratrace dose in various tissues of rats using AMS technique and obtained the first data on urea metabolism in the organism after an ultratrace dose.

The experimental results showed that after oral administration of 2.044×10–6 mg/kg (2.058×10–3 μCi/kg) 14C urea, the presence of 14C urea was detected in all tissues. The radiopharmaceutical concentration reached a peak at 0.25 hr in plasma (1.323×10–3 ng/mL) and at 0.5 hr in stomach and most tissues, which indicated that the oral absorption rate of urea is very fast. The radiopharmaceutical concentration in the kidney and bladder was high, and the peak concentration was much higher than in other tissues, which indicated that 14C urea at ultratrace doses is mainly excreted through the kidney-bladder and at a very rapid clearance rate of 79.95 mL/h/kg, which is consistent with the way by which conventional doses of urea are mainly excreted (Marshall et al. Reference Marshall and Surveyor1988). The low radiopharmaceutical concentration in the brain, fat, and muscle may be related to the plasma-brain barrier and the water solubility of urea, which is similar to the distribution of urea in rats and humans (Nomura et al. Reference Nomura and Matsumoto2006; Park et al. Reference Park, Dae and Han2012; Dickerson et al. Reference Dickerson, Lee and Keshava2018; Rapoport et al. Reference Rapoport, Fitzhugh and Pettigrew1982; Juhr et al. Reference Juhr and Franke1987, Reference Juhr and Franke1990). This distribution study of an ultratrace dose of 14C urea in rats has successfully demonstrated that AMS technology can be applied in the field of pharmacokinetics and radiopharmaceutical distribution research for ultratrace doses, which is difficult to achieve with traditional methods. The 14C-AMS technology developed in this work is expected to be a potential analytical method for the long-term evaluation of pharmacokinetics and radiopharmaceutical distribution research and provide crucial scientific guidance for pharmacokinetics in human subjects.

ACKNOWLEDGMENTS

This work was supported by the Central Government Guidance Funds for Local Scientific and Technological Development, China (No. Guike ZY22096024), the Guangxi Natural Science Foundation of China (No. 2017GXNSFFA198016), and the National Natural Science Foundation of China (Nos. 11775057, 11765004, and 12164006).

SUPPLEMENTARY MATERIAL

To view supplementary material for this article, please visit https://doi.org/10.1017/RDC.2024.47

Footnotes

Selected Papers from the 24th Radiocarbon and 10th Radiocarbon & Archaeology International Conferences, Zurich, Switzerland, 11–16 Sept. 2022.

References

REFERENCES

Bennett, CL, Beukens, RP, Clover, MR, et al. 1997. radiocarbon dating using electrostatic accelerators: negative ions provide the key. Science 198(4316):508510.CrossRefGoogle Scholar
Cheng, P, Burr, GS, Zhou, W, et al. 2019. The deficiency of organic matter 14C dating in Chinese Loess-paleosol sample. Quaternary Geochronology 56:101051.CrossRefGoogle Scholar
D’Souza, RA, Partridge, EA, Roberts, DW, et al. 2007. Distribution of radioactivity and metabolite profiling in tumor and plasma following intravenous administration of a colchicine derivative (14C - ZD6126) to tumor-bearing mice. Xenobiotica 37(3):328 CrossRefGoogle Scholar
Dickerson, AS, Lee, JS, Keshava, C, et al. 2018. Assessment of health effects of exogenous urea: summary and key findings. Current Environmental Health Reports 5(2):205212.CrossRefGoogle ScholarPubMed
FDA, CDER, CBER. 2010. Draft Guidance for Industry: Investigational New Drug Applications (INDs)—Determining Whether Human Research Studies Can Be Conducted Without an IND.Google Scholar
FDA, CDER, CBER. 2010. Guidance for Industry and Researchers: The Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application.Google Scholar
Juhr, NC, Franke, J. 1987. [Metabolism of C14-labelled urea in conventional, germ-free and specifically associated rats]. Zeitschrift für Versuchstierkunde 29(3-4):157164.Google ScholarPubMed
Juhr, NC, Franke, J. 1990. Metabolism of 14C-labeled urea in conventional and bacteria-free guinea pigs]. Zeitschrift für Versuchstierkunde 33(3):123.Google ScholarPubMed
Jull, AJT, Donahue, DJ, Hatheway, AL. 1986. Production of graphite targets by deposition from CO/H2 for precision accelerator 14C measurements. Radiocarbon 28(2A):191197.CrossRefGoogle Scholar
Kaye, B, Garner, RC, Mauthe, RJ, et al. 1997. A preliminary evaluation of accelerator mass spectrometry in the biomedical field. Journal of Pharmaceutical & Biomedical Analysis 16(3):541.CrossRefGoogle ScholarPubMed
L’Annunziata, M, Kessler, MJ. 1998. Handbook of radioactivity analysis. Academic Press.Google Scholar
Lappin, G, Garner, RC. 2003. Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. Handbook of Analytical Separations 4(03):331349.CrossRefGoogle Scholar
Lappin, G, Garner, RC. 2005. The use of accelerator mass spectrometry to obtain early human ADME /PK data. Expert Opin Drug Metab Toxicol 1(1) : 2331.CrossRefGoogle ScholarPubMed
Li, Q, Xie, L, Zhang, J, et al. 2008. The distribution pattern of intravenous [14C] artesunate in rat tissues by quantitative whole-body autoradiography and tissue dissection techniques. Journal of Pharmaceutical and Biomedical Analysis 48(3):876884.CrossRefGoogle ScholarPubMed
Li, Z, Conti, PS. 2010. Radiopharmaceutical chemistry for positron emission tomography. Advanced Drug Delivery Reviews 62(11):10311051.CrossRefGoogle ScholarPubMed
Lubritto, C, Rogalla, D, Rubino, M, et al. 2004. Accelerator mass spectrometry at the 4 MV Dynamitron Tandem in Bochum. Nuclear Instruments & Methods in Physics Research 255260.CrossRefGoogle Scholar
Marshall, BJ, Surveyor, I. 1988. Carbon-14 urea breath test for the diagnosis of campylobacter pylori associated gastritis. Journal of Nuclear Medicine 29(1): 11.Google ScholarPubMed
Mary, Pack A, Monica, et al. 2011. A method for measuring methane oxidation rates using lowlevels of 14C-labeled methane and accelerator mass spectrometry. Limnology and Oceanography: Methods 9(6):245260.Google Scholar
Marzaioli, F, Lubritto, C, Battipaglia, et al. 2005. Reconstruction of past CO2 concentration at a natural CO2 vent site using radiocarbon dating of tree rings. Radiocarbon 47(2):257263.CrossRefGoogle Scholar
Nelson, DE, Korteling, RG, Stott, WR. 1977. Carbon-14: Direct Detection at Natural Concentrations. Science 198(4316):507508.CrossRefGoogle ScholarPubMed
Nielsen, ES. 1952. The use of radioactive carbon (C14) for measuring organic production in the sea. Ices Journal of Marine Science 18:117140.CrossRefGoogle Scholar
Nomura, N, Matsumoto, S, et al. 2006. Disposition of exogenous urea and effects of diet in rats. Arzneimittel-Forschung 56(3):258266.Google ScholarPubMed
Orsovszki, G., & Rinyu, L.. (2015). Flame-sealed tube graphitization using zinc as the sole reduction agent: precision improvement of environmicadas 14c measurements on graphite targets. Radiocarbon, 57(05), 979990.CrossRefGoogle Scholar
Park, SH, Dae, HS, Han, JC, et al. 2012. Pharmacokinetics and excretion into expired air of urea, a potential diagnosis reagent of helicobacter pylori infection. Korean Journal of Clinical Pharmacy 22(2):160166.Google Scholar
Partridge, EA, D’Souza, RA, Lenz, EM, et al. 2008. Disposition and metabolism of the colchicine derivative [14C]-zd6126 in rat and dog. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 38(4):399.CrossRefGoogle ScholarPubMed
Rapoport, SI, Fitzhugh, R, Pettigrew, KD, et al. 1982. Drug entry into and distribution within brain and cerebrospinal fluid: [14C]urea pharmacokinetics. American Journal of Physiology Regulatory Integrative & Comparative Physiology 242(3):R339R348.CrossRefGoogle ScholarPubMed
Salehpour, M, Hakansson, K, Possnert, G. 2015. Small sample accelerator mass spectrometry for biomedical applications. Nuclear Instruments and Methods in Physics Research, Section B. Beam Interactions with Materials and Atoms 361: 4347.CrossRefGoogle Scholar
Sandhu, P. 2004. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metabolism & Disposition 32(11):12541259.CrossRefGoogle Scholar
Schütz, H. 2012. Evaluation of replicate designs for (reference scaled) average bioequivalence according to FDA’s guidances with Phoenix™ WinNonlin® (2012 Pharsight, A Certara Company, Tripos L.P.).Google Scholar
Shen, H, Tang, J, Wang, L, et al. 2022a. New sample preparation line for radiocarbon measurements at the GXNU Laboratory. Radiocarbon 64(6):15011511.CrossRefGoogle Scholar
Shen, H, Shi, S, Tang, J, et al. 2022b. 14C-AMS technology and its applications to an oil field tracer experiment. Radiocarbon 64(5):11591169.CrossRefGoogle Scholar
Slota, PJ, Jull, AJT, Linick, TW, et al. 1987. Preparation of small samples for 14C accelerator targets by catalytic reduction of CO. Radiocarbon 29(2):303306.CrossRefGoogle Scholar
Turteltaub, KW, Felton, JS, Gledhill, BL, et al. 1990. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proceedings of the National Academy of Sciences of the United States of America 87(14):52885292.CrossRefGoogle ScholarPubMed
Turteltaub, KW, Mauthe, RJ, Dingley, KH, et al. 1997. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat Res 376(1–2):243252.CrossRefGoogle ScholarPubMed
Walker, BD, Xu, X. 2019. An improved method for the sealed-tube zinc graphitization of microgram carbon samples and C-14 AMS measurement. Nuclear Instruments and Methods in Physics Research, Section B. Beam Interactions with Materials and Atoms 438:5865.CrossRefGoogle Scholar
Weiss, HM, Wirz, B, Schweitzer, A, et al. 2007. ADME investigations of unnatural peptides: distribution of a 14C-labeled β 3-Octaarginine in rats. Chemistry & Biodiversity 4(7):14131437.CrossRefGoogle ScholarPubMed
Young, G, Ellis, W, Ayrton, J, et al. 2008. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 31(8–9):619632.CrossRefGoogle Scholar
Figure 0

Figure 1 A glass vacuum line for graphite preparation.

Figure 1

Figure 2 Graphite recovery of biological samples.

Figure 2

Table 1 Biological C, H, N, and S content in dried plasma and tissues.

Figure 3

Figure 3 Radiopharmaceutical concentrations in plasma of rats after oral administration of 14C urea.

Figure 4

Table 2 Pharmacokinetic parameters of 14C-urea determined by accelerator mass spectrometry after oral administration in fasted rats.

Figure 5

Table 3 14C-urea concentrations in tissues after oral administration in fasted rats.

Figure 6

Figure 4 14C-urea concentrations in tissues of rats after oral administration of 14C urea.

Supplementary material: File

Wang et al. supplementary material

Wang et al. supplementary material
Download Wang et al. supplementary material(File)
File 498.5 KB